The phase III OlympiA study assessed olaparib in patients with high-risk HER2-negative germline BRCA1/2-mutated breast cancer randomized to 1-year adjuvant olaparib vs. placebo.34 The 3-year invasive, disease-free survival was greater in patients treated with olaparib vs. patients administered placebo (85.9% vs. 77.1%; hazard ratio for invasive disease or death, 0.58; 99.5% CI, 0.41-0.82; P < .001).34 Results from the OlympiA study suggest that PARP inhibitors have a substantial role in the treatment of patients with a germline BRCA mutation and early breast cancer. This evidence concerns the gene BRCA1 and breast cancer.